37 results on '"Kastelein, John J.P."'
Search Results
2. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
3. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
4. Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study
5. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein
6. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care
7. Diagnosis and treatment of familial hypercholesterolaemia
8. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden
9. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants
10. De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
11. Antisense oligonucleotides for the treatment of dyslipidaemia
12. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia
13. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
14. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
15. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
16. Varespladib: targeting the inflammatory face of atherosclerosis
17. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients
18. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women
19. Assessment of atherosclerosis: the role of flow-mediated dilatation
20. C-reactive protein is a mediator of cardiovascular disease
21. The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway
22. Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia
23. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction
24. Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia
25. Gene-load score of the renin–angiotensin–aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia
26. Ultrasound imaging techniques for the evaluation of cardiovascular therapies
27. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study
28. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia
29. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study
30. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing
31. Predictive value of mild, residual descending aortic narrowing for blood pressure and vascular damage in patients after repair of aortic coarctation
32. Can we afford not to screen for FH?
33. Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia
34. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
35. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients
36. Predictive value of mild, residual descending aortic narrowing for blood pressure and vascular damage in patients after repair of aortic coarctation
37. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.